These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 196736)
21. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. Radice PA; Bunn PA; Ihde DC Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026 [No Abstract] [Full Text] [Related]
22. [A phase II study of etoposide (NK 171) in small cell lung cancer--comparison of results between intravenous administration and oral administration]. Furuse K Gan To Kagaku Ryoho; 1985 Dec; 12(12):2352-7. PubMed ID: 3000299 [TBL] [Abstract][Full Text] [Related]
23. Cis-dichlorodiammineplatinum (II) and VP 16-213 combination chemotherapy for non-small cell lung cancer. Goldhirsch A; Joss RA; Cavalli F; Sonntag RW; Brunner KW Med Pediatr Oncol; 1981; 9(3):205-8. PubMed ID: 6264280 [TBL] [Abstract][Full Text] [Related]
24. VP-16-213 therapy in patients with small-cell carcinoma of the lung after failure on combination chemotherapy. Tempero M; Kessinger A; Lemon HM Cancer Clin Trials; 1981; 4(2):155-7. PubMed ID: 6265110 [No Abstract] [Full Text] [Related]
25. Multicenter Phase II trial of etoposide in refractory small cell lung cancer. Issell BF; Einhorn LH; Comis RL; Lawson RD; Baker LH; Harvey HA; Lanzotti VA; Wampler GL; Daniels JR; Anderson PN Cancer Treat Rep; 1985 Jan; 69(1):127-8. PubMed ID: 2981617 [No Abstract] [Full Text] [Related]
26. VP-16-213 and cyclophosphamide in small cell lung cancer: a long-term followup report. Britell JC; Eagan RT; Lee RE Cancer Treat Rep; 1979; 63(11-12):2130-1. PubMed ID: 230899 [No Abstract] [Full Text] [Related]
27. [Experiences with VP-16 in combination with cyclophosphamide or adriamycin in the anaplastic, predominantly small cell bronchogenic carcinoma]. Schmieder HA; Jungi WF; Mayr AC; Senn HJ Schweiz Med Wochenschr; 1979 Jun; 109(22):841-4. PubMed ID: 462156 [TBL] [Abstract][Full Text] [Related]
28. [A phase II clinical trial of oral VP 16-213 in advanced non-Hodgkin's lymphoma]. Nakada H; Ogawa M; Ingaki J; Horikoshi N; Inoue K; Usui N; Adachi K; Tada A; Yamazaki H; Mukaiyama T Gan To Kagaku Ryoho; 1984 Aug; 11(8):1644-8. PubMed ID: 6476837 [TBL] [Abstract][Full Text] [Related]
29. [Phase I study of an oral administration of VP 16-213]. Ogawa M; Ota K; Oyama A; Fukuoka M; Takada M; Yoshida S; Sanpi K; Kimura I; Ohnoshi T; Kuraishi Y Gan To Kagaku Ryoho; 1983 Nov; 10(11):2403-7. PubMed ID: 6639102 [TBL] [Abstract][Full Text] [Related]
31. Small-cell bronchogenic carcinoma--primary and relapse therapy with etoposide (VP-16), methotrexate and CCNU. Niederle N; Krischke W; Bremer K; Schmidt CG; Seeber S Cancer Treat Rev; 1982 Jun; 9 Suppl():101-5. PubMed ID: 6290053 [No Abstract] [Full Text] [Related]
32. [Phase II study of etoposide (NK 171) in advanced hematological malignancies]. Yoshida T; Nakanishi J; Ito K; Kobayashi S; Ohtake S; Nakamura S; Hattori K Gan To Kagaku Ryoho; 1984 Aug; 11(8):1579-84. PubMed ID: 6476835 [TBL] [Abstract][Full Text] [Related]
33. Oral VP-16-213 in advanced bronchogenic carcinoma and toxic effects when combined with methotrexate. Anderson G; Bowyer F; Williams L Thorax; 1981 Jun; 36(6):462-4. PubMed ID: 7314017 [TBL] [Abstract][Full Text] [Related]
34. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial. Faylona EA; Loehrer PJ; Ansari R; Sandler AB; Gonin R; Einhorn LH J Clin Oncol; 1995 May; 13(5):1209-14. PubMed ID: 7738623 [TBL] [Abstract][Full Text] [Related]
35. A clinical trial of the oral form of 4'-demethyl-epipodophyllotoxin-beta-D ethylidene glucoside (NSC 141540) VP 16-213. Falkson G; van Dyk JJ; van Eden EB; van der Merwe AM; van den Bergh JA; Falkson HC Cancer; 1975 Apr; 35(4):1141-4. PubMed ID: 163675 [TBL] [Abstract][Full Text] [Related]
36. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920 [TBL] [Abstract][Full Text] [Related]
37. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Girling DJ Lancet; 1996 Aug; 348(9027):563-6. PubMed ID: 8774567 [TBL] [Abstract][Full Text] [Related]
38. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent. Sinkule JA Pharmacotherapy; 1984; 4(2):61-73. PubMed ID: 6326063 [TBL] [Abstract][Full Text] [Related]
39. VP-16 plus cyclophosphamide in the treatment of advanced lung cancer. Estape J; Milla A; Agusti A; Sanchez-Lloret J; Santabarbara P; Rozman C Cancer; 1983 Feb; 51(3):385-9. PubMed ID: 6295601 [TBL] [Abstract][Full Text] [Related]
40. The role of VP-16 in the treatment of small-cell lung cancer: studies of the West of Scotland Lung Cancer Group. Banham S; Dorward A; Hutcheon A; Ahmedzai S; Cunningham D; Burnett A; Soukop M; Lucie N; Kaye S Semin Oncol; 1985 Mar; 12(1 Suppl 2):2-6. PubMed ID: 2983433 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]